Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,175 INR
Change Today -19.75 / -1.65%
Volume 2.8M
GNP On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 7:05 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

glenmark pharmaceuticals ltd (GNP) Snapshot

Open
1,205
Previous Close
1,195
Day High
1,210
Day Low
1,158
52 Week High
08/21/15 - 1,263
52 Week Low
09/26/14 - 676.00
Market Cap
331.5B
Average Volume 10 Days
2.3M
EPS TTM
17.52
Shares Outstanding
282.2M
EX-Date
--
P/E TM
67.1x
Dividend
2.00
Dividend Yield
0.17%
Current Stock Chart for GLENMARK PHARMACEUTICALS LTD (GNP)

Related News

No related news articles were found.

glenmark pharmaceuticals ltd (GNP) Related Businessweek News

No Related Businessweek News Found

glenmark pharmaceuticals ltd (GNP) Details

Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products. The company’s products include Crofelemer, an anti diarrheal drug for symptomatic relief of non-infectious diarrhoea in patients with HIV/AIDS on anti retro viral therapy; GRC 17536 for neuropathic pain and respiratory disorders; and GRC 27864, an orally bioavailable inhibitor of mPGES-1 to treat chronic inflammatory conditions, which is in Phase I trial. Its products also comprise Vatelizumab (GBR 500) that is in Phase II study for multiple sclerosis; GBR 900, which is in is Phase I trial for the treatment of chronic pain targeting TrkA, the receptor of nerve growth factor; and GBR 830, an anti-OX40 monoclonal antibody for autoimmune disorders. In addition, the company is involved in the formulations business that focuses on therapeutic areas, such as dermatology, anti-infectives, respiratory, cardiac, diabetes, gynecology, CNS, and oncology. It has operations in India, Latin America, Europe, the United States, and internationally. Glenmark Pharmaceuticals Limited was founded in 1977 and is headquartered in Mumbai, India.

Founded in 1977

glenmark pharmaceuticals ltd (GNP) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: 57.1M
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 16.3M
Director of Corporate Affairs, Executive Dire...
Total Annual Compensation: 18.3M
Compensation as of Fiscal Year 2014.

glenmark pharmaceuticals ltd (GNP) Key Developments

Glenmark Pharmaceuticals Europe Ltd. Wins GBP 11.2 Million Multiple Awardees Contract for Supplying Psychiatry Medicines

Glenmark Pharmaceuticals Europe Ltd. won a GBP 11.2 million multiple awardees contract award from The Common Services Agency (more commonly known as NHS National Services Scotland) ("the Authority") for the supply of psychiatry medicines (All other psychiatry medicines) (Contract Award Notice No.: 2015/S 162-296520; Lot No.: 5).

Glenmark Pharmaceuticals Inc. Receives United States Food & Drug Administration Approval for Drospirenone and Ethinyl Estradiol Tablets USP, 3 Mg/0.02 Mg

Glenmark Pharmaceuticals Inc. has been granted final approval by the United States Food & Drug Administration for Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg, the generic version of Yaz Tablets of Bayer HealthCare Pharmaceuticals Inc. (Bayer). Glenmark plans to commence shipping of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg immediately.

Glenmark Pharmaceuticals Ltd. Reports Audited Standalone and Consolidated Earnings Results for the First Quarter Ended June 30, 2015

Glenmark Pharmaceuticals Ltd. reported audited standalone and consolidated earnings results for the first quarter ended June 30, 2015. For the quarter, on standalone basis, the company reported net sales/income from operations (net of excise duty) of INR 12,259.03 against INR 5,932.22 million for the same period in the last year. Profit from operations before other income, finance costs and exceptional items was INR 4,010.05 million against INR 1,135 million for the same period in the last year. Profit from ordinary activities before tax was INR 4,187.93 million against INR 1,217.57 million for the same period in the last year. Net profit was INR 3,352.02 million against INR 1,039.34 million for the same period in the last year. Earnings per diluted share before and after extraordinary items (not annualized) were INR 12.12 against INR 3.83 for the same period in the last year. For the quarter, on consolidated basis, the company reported net sales/income from operations (net of excise duty) of INR 16,258.32 million against INR 14,778.19 million for the same period in the last year. Profit from operations before other income, finance costs and exceptional items was INR 2,898.36 million against INR 2,772.67 million for the same period in the last year. Profit from ordinary activities before tax was INR 2,532.92 million against INR 2,326.11 million for the same period in the last year. Net profit was INR 1,782.35 million against INR 1,848.97 million for the same period in the last year. Earnings per diluted share before and after extraordinary items (not annualized) were INR 6.45 against INR 6.81 for the same period in the last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GNP:IN 1,174.75 INR -19.75

GNP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Cadila Healthcare Ltd 1,929 INR +27.35
Impax Laboratories Inc $42.40 USD -1.57
Jubilant Life Sciences Ltd 352.05 INR -2.85
Lannett Co Inc $49.87 USD -0.17
Taro Pharmaceutical Industries Ltd $134.91 USD +0.30
View Industry Companies
 

Industry Analysis

GNP

Industry Average

Valuation GNP Industry Range
Price/Earnings 64.3x
Price/Sales 4.6x
Price/Book 10.3x
Price/Cash Flow 43.6x
TEV/Sales 4.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLENMARK PHARMACEUTICALS LTD, please visit www.glenmarkpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.